Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSGeneric

FONDAPARINUX SODIUM

FONDAPARINUX SODIUM

Standard Dose
7.5MG/0.6ML (7.5MG/0.6ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview FONDAPARINUX SODIUM is listed in Drugs@FDA under application 216493 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient FONDAPARINUX SODIUM Form and strength SOLUTION;SUBCUTANEOUS - 7.5MG/0.6ML (7.5MG/0.6ML) Sponsor HANGZHOU ZHONGMEI Submission history Latest submission status date: 2024-08-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview FONDAPARINUX SODIUM is listed in Drugs@FDA under application 216493 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FONDAPARINUX SODIUM Form and strength SOLUTION;SUBCUTANEOUS - 7.5MG/0.6ML (7.5MG/0.6ML) Sponsor HANGZHOU ZHONGMEI Submission history Latest submission status date: 2024-08-19 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.